Buchumschlag

Benefit of patients with an early and progressed state of hepatocellular carcinoma treated with drug-eluting beads

Aim: To evaluate drug-eluting beads (DEB) for transarterial chemoembolization (TACE) in patients with Barcelona Clinic Liver Cancer (BCLC) A to D suffering from hepatocellular carcinoma. Material and Methods: The progression-free interval (PFI), survival and laboratory findings of 46 patients were r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Rathmann, Nils-Andreas (VerfasserIn) , Sadick, Maliha (VerfasserIn) , Rathmann, Björn (VerfasserIn) , Kostrzewa, Michael (VerfasserIn) , Weiß, Christel (VerfasserIn) , Schönberg, Stefan (VerfasserIn) , Diehl, Steffen J. (VerfasserIn) , Antoni, Christoph Helmer (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: September-October 2016
In: In vivo
Year: 2016, Jahrgang: 30, Heft: 5, Pages: 707-712
ISSN:1791-7549
Online-Zugang:Verlag, Volltext: http://iv.iiarjournals.org/content/30/5/707
Volltext
Verfasserangaben:Nils Rathmann, Maliha Sadick, Bjoern Rathmann, Michael Kostrzewa, Christel Weiss, Stefan O. Schoenberg, Steffen J. Diehl and Christoph Antoni
Beschreibung
Zusammenfassung:Aim: To evaluate drug-eluting beads (DEB) for transarterial chemoembolization (TACE) in patients with Barcelona Clinic Liver Cancer (BCLC) A to D suffering from hepatocellular carcinoma. Material and Methods: The progression-free interval (PFI), survival and laboratory findings of 46 patients were retrospectively analyzed after DEB TACE. Results: The mean survival interval was 16.93 months. The BCLC A/B group had significantly (p=0.01) longer survival compared to C/D: 20.44 and 10.36 months. Mean PFI was 10.75 months with a significantly (p=0.002) longer PFI of the BCLC A/B group (12.71 months) compared to BCLC C/D (3.91 months). In terms of possible adverse events (AEs) significant changes (p<0.05) were observed in cholinesterase, white blood cells, alkaline phosphatase and C-reactive protein. Conclusion: Mean survival and PFI results in the BCLC A/B patient group were comparable to historical controls. In addition, the results suggest that patients with BCLC stage C/D also benefited from DEB TACE.
Beschreibung:Gesehen am 14.01.2019
Beschreibung:Online Resource
ISSN:1791-7549

Ähnliche Einträge